

**Alpha-1 Adrenergic Blockers**  
**Cardura (doxazosin)**  
**Effective 01/01/2024**

<b>Plan</b>	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Benefit</b>	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
<b>Specialty Limitations</b>	N/A		
<b>Contact Information</b>	<b>Medical Benefit</b> <b>Pharmacy Benefit</b>	Phone: 833-895-2611 Phone: 800-711-4555	Fax: 888-656-6671 Fax: 844-403-1029
<b>Exceptions</b>	N/A		

### Overview

Cardura is an alpha-1 adrenergic antagonist indicated for benign prostatic hyperplasia (BPH) and the treatment of hypertension.

### Coverage Guidelines

Authorization may be granted for members new to the plan who are currently receiving treatment with the requested medication, excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

#### OR

Authorization may be granted when ONE of the following criteria is met:

1. Member has experienced an inadequate treatment response after at least a 30-day trial of a generic alpha-1 adrenergic blocker drug.
2. Member has a documented contraindication to or a potential drug interaction with a generic alpha-1 adrenergic blocker drug.
3. Member has had a trial and was intolerant to at least one generic alpha-1 adrenergic blocker drug.

### Limitations

1. Initial approvals will be granted for 24 months.

### References

N/A

### Review History

12/13/2023: Reviewed at Dec P&T, switched from SGM to Custom. Effective 1/1/2024